Search PubMed⌕ Search

Biomedical subjects

M Zimmer

Publications and source records attributed to M Zimmer.

150 records · Page 9Linked to original sources

Control of glial cell volume in anoxia. In vitro studies on ischemic cell swelling.

Volume regulation of C6 glial cells was studied in anoxia in vitro to improve the understanding of ischemic cell swelling in the brain. Contrary to in vivo conditions, anoxia or anoxia plus iodoacetate for additional inhibition of anaerobic energy metabolism did not induce glial swelling. However, intracellular K+ was markedly decreased while intracellular Na+ increased. Induction of energy failure by anoxia plus iodoacetate was found to prevent the regulatory volume decrease on hyposmotic exposure of the cells, which is regularly observed in normoxic control conditions. Hyposmotic exposure in anoxia plus iodoacetate led only to an initial tendency of cell volume normalization followed by secondary cell swelling. This was associated with a net increase of intracellular Na+ that may explain the failure of volume regulation under these circumstances. Maintenance of a normal glial cell size during complete energy deprivation by anoxia plus iodoacetate in isotonic medium strongly indicates that energy failure per se does not suffice to induce cell swelling. Cell swelling in cerebral ischemia in vivo thus is likely to require additional mechanisms, most likely an increase of membrane permeability to Na+, which may be caused by release and accumulation of excitotoxins such as glutamate or by an extracellular release of K+. Such a mechanism would hardly influence the extracellular homeostasis in vitro due to the large medium-to-cell volume ratio. The findings demonstrate, nonetheless, the significance of a competent energy metabolism to support cell volume regulation. This is concluded from the failure of regulatory volume decrease of hypotonically suspended glial cells in anoxia plus iodoacetate.(ABSTRACT TRUNCATED AT 250 WORDS)

Cell Line↗

Albumin kinetics in hypoalbuminemic patients receiving total parenteral nutrition.

BACKGROUND: By using undenatured purified albumin preparations radiolabeled with iodine, the half-life of serum albumin in well patients who are stable is known to be approximately 17 days. However, when a patient is suffering with an acute illness such as sepsis, trauma, burns or after an extensive operative procedure, the serum albumin level decreases. It is not known whether this fall in serum albumin is due to increased catabolism, decreased synthesis, or a combination of both factors. This study explores the kinetics of albumin catabolism under these circumstances to clarify the issue. METHODS: 125I-labeled albumin was administered intravenously to 10 critically ill, hypoalbuminemic patients receiving total parenteral nutrition (TPN). Each subject had frequent blood samples taken for at least 10 days to measure the decline of plasma radioactivity over time. None was receiving unlabeled albumin during the investigation. It was assumed that the plasma decay would follow first-order kinetics after the early equilibration phase. Radioactivity of heparinized blood samples (counts/2 mL sample) were counted and the results were graphically expressed. RESULTS: One subject was not evaluated because he was discharged on the 8th day. The APACHE (acute physiology and chronic health evaluation) score for the other nine subjects ranged from 4 to 18 (mean, 7.5). The serum albumin remained below 3.0 g/dL in each subject and did not change statistically throughout the study. The radioiodinated albumin half-life ranged from 5.52 to 11.76 days (mean 9.10 days; compared with published normal of approximately 17 days). The equilibration time was 3 to 7 days. The average albumin catabolized for this group is similar to previously reported normal subjects, 0.18 g/kg/d. CONCLUSION: Hypoalbuminemic patients receiving TPN have markedly shortened plasma albumin half-lives, but the albumin catabolized per day is similar to normal patients. These data argue for both a synthetic and catabolic defect that explains the hypoalbuminemia in this patient group.

APACHE↗

[The role of the dentist Christopher Starr Brewster and of certain physicians of American origins in the debut of anesthesia].

Francis Willis Fisher (1821-1877), son of Freeman Fisher (1787-1860) and Mary Godfrey Bronson (1802-1885), was the nephew of the painter Alvan Fisher (1792-1863) and of the physician John Dix Fisher (1797-1850). At the beginning of December 1846, having made an appointment with a Parisian dentist for the extraction of a tooth, F. Willis Fisher resolved to experiment the new application of sulphuric ether. The dental office where he went with other professional men could have been that of his American colleague, Christopher Starr Brewster (1799-1870). Brewster was a pioneer in the field of anaesthesia. On 22 January 1847, he successfully administered the ether to his patients. Brewster was a friend of the dentist Horace Wells (1815-1848) and of James Henry Bennet (1816-1891), Vice-President of the Parisian Medical Society (1841-1843), then the Physician-Accoucheur to the Western General Dispensary of London (1845-1850). On 8 June 1848, Brewster married Anna Maria Bennet. Two children were born from this union: Henry Bennet Brewster and Mary Catherine Brewster.

Anesthesiology↗

[Interaction of isoxicam and digoxin].

The influence of maintenance therapy with Isoxicam, 200 mg daily, on digoxin steady-state plasma levels was studied on 12 healthy volunteers. One person dropped out from the investigation program on account of cardiac sensations following the invasion phase with digoxin. No statistically significant differences could be shown during concomitant therapy or after withdrawal of Isoxicam. Neither were toxic glycoside plasma concentrations observed. There were no pathological clinicochemical parameters, in particular no changes in renal function values.

Acetyldigoxins↗

[Indomethacin kinetics in synovia and plasma following administration of indomethacin Gits 7/85 in patients with chronic polyarthritis].

Patients suffering from rheumatoid arthritis received a single dose of the new therapeutic system of indomethacin (Gits 7/85). Samples of plasma and synovial fluid were taken after 1, 2, 4, 6, 8, 10, 12, and 24 h. Concentration peaks could not be observed. After 2-3 h plasma levels were achieved which remained constant over the investigational period. Indomethacin concentrations in synovial fluid were seen with some delay. All synovial fluid levels after single application were lower than the plasma concentrations. The kinetics of elimination showed no difference between the two compartments. The above findings confirm the expectations regarding the new therapeutic system of indomethacin (Gits 7/85), i.e., the maintenance of a nearly constant plasma and synovia level for at least 10 h. The avoidance of peaks is seen as an additional advantage.

Arthritis, Rheumatoid↗